Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine

Affiliations

Comment

Bivas Biswas. J Clin Oncol. 2015.

. 2015 Feb 10;33(5):524.

doi: 10.1200/JCO.2014.57.5621. Epub 2015 Jan 12.

No abstract available

Comment in

Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas.
Kawaguchi T, Ando M, Kubo A. Kawaguchi T, et al. J Clin Oncol. 2015 Feb 10;33(5):526-7. doi: 10.1200/JCO.2014.58.5315. Epub 2015 Jan 12. J Clin Oncol. 2015. PMID: 25584006 No abstract available.

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Kawaguchi T, et al. J Clin Oncol. 2014 Jun 20;32(18):1902-8. doi: 10.1200/JCO.2013.52.4694. Epub 2014 May 19. J Clin Oncol. 2014. PMID: 24841974 Clinical Trial.